1
|
Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC. Vaccination of Adults With Cancer: ASCO Guideline. J Clin Oncol 2024; 42:1699-1721. [PMID: 38498792 PMCID: PMC11095883 DOI: 10.1200/jco.24.00032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Accepted: 01/11/2024] [Indexed: 03/20/2024] Open
Abstract
PURPOSE To guide the vaccination of adults with solid tumors or hematologic malignancies. METHODS A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the efficacy and safety of vaccines used by adults with cancer or their household contacts. This review builds on a 2013 guideline by the Infectious Disease Society of America. PubMed and the Cochrane Library were searched from January 1, 2013, to February 16, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS A total of 102 publications were included in the systematic review: 24 systematic reviews, 14 RCTs, and 64 nonrandomized studies. The largest body of evidence addressed COVID-19 vaccines. RECOMMENDATIONS The goal of vaccination is to limit the severity of infection and prevent infection where feasible. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell-depleting therapy. Active interaction and coordination among healthcare providers, including primary care practitioners, pharmacists, and nursing team members, are needed. Vaccination of household contacts will enhance protection for patients with cancer. Some vaccination and revaccination plans for patients with cancer may be affected by the underlying immune status and the anticancer therapy received. As a result, vaccine strategies may differ from the vaccine recommendations for the general healthy adult population vaccine.Additional information is available at www.asco.org/supportive-care-guidelines.
Collapse
Affiliation(s)
- Mini Kamboj
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
| | - Kari Bohlke
- American Society of Clinical Oncology, Alexandria, VA
| | | | - Kieron Dunleavy
- MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | - Abbey Fueger
- The Leukemia and Lymphoma Society, Rye Brook, NY
| | - Lee Jones
- Fight Colorectal Cancer, Arlington, VA
| | - Amar H Kelkar
- Harvard Medical School, Dana Farber Cancer Institute, Boston, MA
| | | | | | - Per Ljungman
- Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
| | - Eric D Miller
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - Larissa A Meyer
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Heloisa P Soares
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
| | | | | | - Elise C Kohn
- Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD
| |
Collapse
|
2
|
Landt S, Thomas A, Fueger A, Jeschke S, Korlach S, Adam H, Ulm K, Schmid P, Blohmer J, Lichtenegger W, Kuemmel S. Analysis of the VEGF family and their receptors in serum/plasma of patients with pre-invasive and invasive cervical cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5016 Background: The vascular endothelial growth factor (VEGF) family and their receptors are essential regulators of angiogenesis and lymphangiogenesis. This study examined the significance of circulating VEGF, VEGF-C, VEGF-D and their receptors VEGFR-1 and VEGFR-2 in patients with preinvasive and invasive cancer in relation to conventional prognostic parameters. Methods: Blood samples were obtained from 125 women before initial treatment (CIN I-III n = 50; FIGO stage I-IV n = 51; relapse n = 24). Plasma (p) and serum(s) levels of pVEGF, sVEGF-D, sVEGFR-1, sVEGFR-2 (R&D Systems, USA) and sVEGF-C (IBL, Japan) were determined by using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). Results: The highest level of pVEGF (p = 0.007) and sVEGFR-2 (p = 0.014) were detected in patients with recurrent disease, whereas the highest level of sVEGF-D (p = 0.046) were measured in patients with preinvasive lesions (CIN I-III). Furthermore, significantly elevated levels of sVEGF-C (p = 0.021) were detected in early stages (FIGO I-II) in comparison with advanced stages (FIGO III-IV) of cervical cancer. No significant difference in concentration was observed between the various grades of cervical intraepithelial neoplasia (CIN I-III). Correlations between conventional prognostic markers such as lymph node status (N0/N1), lymphangioinvasion (L0/L1), angioinvasion (V0/V1) and grading (G1/G2/G3) were investigated. Increased plasma levels of VEGF (p = 0.036) correlate with the dissemination of tumor cells to regional lymph nodes (N1),whereas serum VEGF-D levels were significantly decreased in women with lymph-node involvement (N1) (p = 0.045) and vascular invasion (L1) (p = 0.019). None of these members of the VEGF family were found to correlate significantly with histological subtype (squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma) or grading of the tumor cells (G1/G2/G3). Conclusions: These results show that circulating concentrations of VEGF are associated with the stage of disease. In an early stage of cervical cancer a switch to a lymphangiogenic phenotype (VEGF-D, VEGF-C) might be possible. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Landt
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - A. Thomas
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - A. Fueger
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - S. Jeschke
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - S. Korlach
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - H. Adam
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - K. Ulm
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - P. Schmid
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - J. Blohmer
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - W. Lichtenegger
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| | - S. Kuemmel
- Charité Campus Mitte, Berlin, Germany; Stadtspital Waid, Zürich, Switzerland; Technical University, Munich, Germany; Imperial College, London, United Kingdom; Sankt Gertrauden Krankenhaus, Berlin, Germany; Charité Campus Virchow, Berlin, Germany
| |
Collapse
|